Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

Trial Profile

Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs AGEN 2034 (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Agenus
  • Most Recent Events

    • 20 Oct 2018 Results presented in an Agenus media release.
    • 20 Oct 2018 According to an Agenus media release, results from this study were presented at the 2018 European Society for Medical Oncology (ESMO) Congress.
    • 09 Oct 2018 According to an Agenus media release, data will be presented at the European Society for Medical Oncology (ESMO) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top